Literature DB >> 25295144

[Not Available].

Mohamed Zizi1, Imad Ziouziou1, Souhail El Yacoubi1, Mouna Khmou, Ahmed Jahid, Najat Mahassini, Tariq Karmouni1, Khalid El Khader1, Abdellatif Koutani1, Ahmed Iben Attya Andaloussi1.   

Abstract

Year:  2014        PMID： 25295144      PMCID： PMC4164561          DOI： 10.5489/cuaj.676

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN： 1911-6470            Impact factor:   1.862


× No keyword cloud information.
  12 in total

1.  [Yolk sac tumor. Report of a case].

Authors:  A Debbagh; S Bennani; H Jouhadi; A Joual; M el Mrini; A Kahlain; S Benjelloun
Journal:  Ann Urol (Paris)       Date:  2001-11

2.  [Recommendations Onco-Urology 2010: Germ cell testicular tumors.].

Authors:  X Durand; J Rigaud; C Avances; P Camparo; S Culine; F Iborra; N Mottet; P Sèbe; M Soulié
Journal:  Prog Urol       Date:  2010-11       Impact factor: 0.915

3.  [Cancer of the testis. Pathological anatomy].

Authors:  N Berger; J J Voigt
Journal:  Rev Prat       Date:  1993-09-01

4.  Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery.

Authors:  Christian Kollmannsberger; Siamak Daneshmand; Alan So; Kim N Chi; Nevin Murray; Christie Moore; Brandon Hayes-Lattin; Craig Nichols
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

5.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

6.  Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Authors:  Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo N Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

7.  SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma.

Authors:  Dengfeng Cao; Shuangping Guo; Robert W Allan; Kyle H Molberg; Yan Peng
Journal:  Am J Surg Pathol       Date:  2009-06       Impact factor: 6.394

8.  Diagnostic utility of SALL4 in extragonadal yolk sac tumors: an immunohistochemical study of 59 cases with comparison to placental-like alkaline phosphatase, alpha-fetoprotein, and glypican-3.

Authors:  Fenghua Wang; Aijun Liu; Yan Peng; Dinesh Rakheja; Lixin Wei; Debin Xue; Debing Xue; Robert W Allan; Kyle H Molberg; Jianping Li; Dengfeng Cao
Journal:  Am J Surg Pathol       Date:  2009-10       Impact factor: 6.394

9.  SALL4 is a novel diagnostic marker for testicular germ cell tumors.

Authors:  Dengfeng Cao; Jianping Li; Charles C Guo; Robert W Allan; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2009-07       Impact factor: 6.394

10.  SALL4 is a novel sensitive and specific marker for metastatic germ cell tumors, with particular utility in detection of metastatic yolk sac tumors.

Authors:  Dengfeng Cao; Peter A Humphrey; Robert W Allan
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.